Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
The return on equity (ROE) is N/A as of the fiscal period ended Thursday, September 30, 2021.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q3 FY2021 (2021-09-30): -336.89%.
RETURN ON EQUITY (ROE)
N/A
RETURN ON EQUITY (ROE) AVG TTM
-162.12%
RETURN ON EQUITY (ROE) AVG 3Y
-114.62%
RETURN ON EQUITY (ROE) AVG 5Y
-140.11%
RETURN ON EQUITY (ROE) AVG 10Y
-135.36%
RETURN ON EQUITY (ROE) AVG 15Y
-135.36%
RETURN ON EQUITY (ROE) AVG 20Y
-128.04%
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Galectin Therapeutics Inc.
Market Cap
$245.65M
Return on Equity (ROE)
N/A
TTM Avg
-162.12%
3Y Avg
-114.62%
5Y Avg
-140.11%
Market Cap
$244.25M
Return on Equity (ROE)
-118.58%
TTM Avg
62.37%
3Y Avg
-376.78%
5Y Avg
-340.60%
Market Cap
$247.45M
Return on Equity (ROE)
-27.27%
TTM Avg
-92.43%
3Y Avg
-64.95%
5Y Avg
-57.80%
Market Cap
$248.21M
Return on Equity (ROE)
-695.56%
TTM Avg
-3698.55%
3Y Avg
-1897.26%
5Y Avg
-1268.80%
Market Cap
$239.89M
Return on Equity (ROE)
-31.55%
TTM Avg
-30.05%
3Y Avg
-33.97%
5Y Avg
-37.95%
Market Cap
$251.64M
Return on Equity (ROE)
N/A
TTM Avg
-125.28%
3Y Avg
-42.20%
5Y Avg
-43.41%
Market Cap
$239.45M
Return on Equity (ROE)
-25.20%
TTM Avg
-25.82%
3Y Avg
5.12%
5Y Avg
5.12%
Market Cap
$236.56M
Return on Equity (ROE)
-303.61%
TTM Avg
612.49%
3Y Avg
-57.80%
5Y Avg
-87.69%
Market Cap
$259.30M
Return on Equity (ROE)
-38.33%
TTM Avg
-61.68%
3Y Avg
-393.03%
5Y Avg
-278.88%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Galectin Therapeutics Inc. (GALT) | $245.65M | N/A | -162.12% | -114.62% | -140.11% |
| Akebia Therapeutics, Inc. (AKBA)vs › | $244.25M | -118.58% | 62.37% | -376.78% | -340.60% |
| InflaRx N.V. (IFRX)vs › | $247.45M | -27.27% | -92.43% | -64.95% | -57.80% |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $248.21M | -695.56% | -3698.55% | -1897.26% | -1268.80% |
| High Tide Inc. (HITI)vs › | $239.89M | -31.55% | -30.05% | -33.97% | -37.95% |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $251.64M | N/A | -125.28% | -42.20% | -43.41% |
| BioAge Labs Inc. (BIOA)vs › | $239.45M | -25.20% | -25.82% | 5.12% | 5.12% |
| Biodesix, Inc. (BDSX)vs › | $236.56M | -303.61% | 612.49% | -57.80% | -87.69% |
| Eupraxia Pharmaceuticals Inc. (EPRX)vs › | $259.30M | -38.33% | -61.68% | -393.03% | -278.88% |
| Anika Therapeutics, Inc. (ANIK)vs › | $264.05M | -2.76% | -22.10% | -22.09% | -15.95% |
ROE
N/A
ROA
-187.8%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2021-09-30 | -336.89% |
| 2021-06-30 | -166.99% |
| 2021-03-31 | -143.95% |
| 2020-12-31 | -96.99% |
| 2020-09-30 | -65.79% |
| 2020-06-30 | -47.53% |
| 2020-03-31 | -33.86% |
| 2019-12-31 | -29.16% |
| 2019-09-30 | -22.65% |
| 2019-06-30 | -21.65% |
| 2019-03-31 | -175.64% |
| 2018-12-31 | -201.51% |
| 2018-09-30 | -147.51% |
| 2018-06-30 | -152.31% |
| 2018-03-31 | -587.46% |
| 2017-09-30 | -690.79% |
| 2017-06-30 | -319.10% |
| 2017-03-31 | -203.14% |
| 2016-12-31 | -178.41% |
| 2016-09-30 | -178.88% |
| 2016-06-30 | -156.57% |
| 2016-03-31 | -112.61% |
| 2015-12-31 | -79.95% |
| 2015-09-30 | -96.47% |
| 2015-06-30 | -67.49% |
| 2015-03-31 | -54.05% |
| 2014-12-31 | -56.44% |
| 2014-09-30 | -49.62% |
| 2014-06-30 | -45.86% |
| 2014-03-31 | -40.03% |
| 2013-12-31 | -146.93% |
| 2013-09-30 | -897.31% |
| 2013-06-30 | -290.10% |
| 2013-03-31 | -190.95% |
| 2012-12-31 | -122.21% |
| 2012-09-30 | -348.94% |
| 2012-06-30 | -203.95% |
| 2012-03-31 | -153.47% |
| 2011-06-30 | -803.93% |
| 2007-06-30 | 698.22% |
| 2007-03-31 | 993.32% |
| 2005-12-31 | -182.64% |
| 2005-09-30 | -130.55% |
| 2005-06-30 | -100.44% |
| 2005-03-31 | -77.47% |
| 2004-12-31 | -71.06% |
| 2004-09-30 | -53.95% |
| 2004-06-30 | -73.34% |
| 2004-03-31 | -98.80% |
| 2003-12-31 | -63.92% |
| 2003-09-30 | -93.07% |
| 2003-06-30 | -206.88% |
